Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Methotrexate identified as potential treatment for blood cancers

A screening study in fruit-fly cells (pictured) has identified two existing drugs – the anti-inflammatory and chemotherapeutic drug methotrexate and the closely related drug aminopterin – as potent suppressors of JAK/STAT activation

Source: Miguel Arocena, University of Dundee / Science Photo Library

Fruit fly cells were used a screening tool to find drugs that inhibit a cellular pathway that is activated in certain types of cancers

In many different cancers the cellular pathway JAK/STAT is activated. Thus, the pathway is an attractive therapeutic target, especially for malignancies of the bone marrow called myeloproliferative neoplasms (MPNs). Pharmacological JAK inhibitors, such as ruxolitinib, are available but are expensive and are often associated with side effects.

Now, a screening study in fruit-fly cells has identified two existing drugs — the anti-inflammatory and chemotherapeutic drug methotrexate and the closely related drug aminopterin — as potent suppressors of JAK/STAT activation.

“These effects occurred at drug concentrations already routinely prescribed for rheumatoid arthritis patients,” the authors report in PLoS One (online, 1 July 2015)[1]. “We suggest that patients with JAK/STAT-associated haematological malignancies may benefit from low-dose methotrexate treatments.” 

Noting that methotrexate is a low-cost and well-characterised drug, the researchers will now undertake clinical trials of methotrexate as a therapy in MPNs and other haematological malignancies.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068921

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • A screening study in fruit-fly cells (pictured) has identified two existing drugs – the anti-inflammatory and chemotherapeutic drug methotrexate and the closely related drug aminopterin – as potent suppressors of JAK/STAT activation

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.